Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinazolinone SCHEMBL88525 | 0.74 | PARP1 (1.00) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| 4-Aminoquinazoline SCHEMBL9375368 | 0.74 | SMN1; SMN2 (0.59) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| SCHEMBL6836398 | 0.74 | KDM4A (0.49) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| Quinazolinone SCHEMBL8201420 | 0.72 | PARP1 (0.96) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| Quinazolinone SCHEMBL22442340 | 0.72 | PARP1 (0.96) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| Quinazolinone SCHEMBL30408864 | 0.72 | PARP1 (0.96) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| SCHEMBL20998623 | 0.72 | PARP1 (0.96) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| Quinazolinone SCHEMBL29603643 | 0.72 | PARP1 (0.96) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| SCHEMBL9263181 | 0.72 | PARP1 (0.64) | PDPK1PARP1SMN1; SMN2RXFP1RAB9A | |
| SCHEMBL202156 | 0.71 | PDPK1 (0.55) | PDPK1CA12PARP1ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1810693-A2 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | Shering Corporation (US) | 2007-07-25 | — | — | EP | claimed |
| CN-1658903-A | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORP (US) | 2005-08-24 | — | — | CN | claimed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | claimed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-20230357261-A1 | ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS | The University of Pittsburgh- of the Commonwealth System of Higher Education | 2023-11-09 | — | — | US | disclosed |
| US-20230357261-A1 | ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS | The University of Pittsburgh- of the Commonwealth System of Higher Education | 2023-11-09 | — | — | US | disclosed |
| EP-3453707-B1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2022-02-16 | — | — | EP | disclosed |
| EP-3453707-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2019-03-13 | — | — | EP | disclosed |
| CN-104059075-B | 8,9-is mono-, disubstituted imidazoles [1,2-c]-quinazoline-3 (2H)-one fused heterocyclic compound and preparation method thereof | ZAOZHUANG UNIVERSITY (CN) | 2015-10-21 | — | — | CN | disclosed |
| CN-103965203-B | Imidazo-[1,2-c]-quinazolin-3(2H)-one fused-heterocycle compounds and preparation method thereof | UNIV ZAOZHUANG | 2015-03-25 | — | — | CN | disclosed |
| CN-104327086-A | 2H-imidazo[1,2-C] quinazoline-3-one compound with optical activity and preparation method thereof | ENGINEERING AND TECHNOLOGY INST OF LUNAN COAL CHEMICAL ENGINEERING | 2015-02-04 | — | — | CN | disclosed |
| EP-0698013-A1 | FUNGICIDAL FUSED BICYCLIC PYRIMIDINONES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-02-28 | — | — | EP | disclosed |
| WO-1995019970-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
| WO-1994026722-A1 | FUNGICIDAL FUSED BICYCLIC PYRIMIDINONES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0411766-B1 | Substituted quinazolinones as angiotensin II antagonists | MERCK & CO INC (US) | 1994-01-19 | — | — | EP | disclosed |
| US-5240928-A | Hypotensive agents | MERCK & CO., INC. (US) | 1993-08-31 | — | — | US | disclosed |
| US-5238942-A | Hypotensive agents | MERCK & CO., INC. (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0512870-A1 | Substituted quinazolinones bearing acidic functional groups as angiotensin II antagonists | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0411766-A1 | Substituted quinazolinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357261-A1 | ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS | AHR, ARNT, MTNR1A | PDPK1 3930/4885CA12 4806/4885PARP1 4174/4885 |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | PDPK1 3009/4885CA12 1696/4885PARP1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.